Morningstar Investment Management LLC Sells 13,112 Shares of Henry Schein, Inc. $HSIC

Morningstar Investment Management LLC lowered its position in Henry Schein, Inc. (NASDAQ:HSIC) by 59.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,787 shares of the company’s stock after selling 13,112 shares during the quarter. Morningstar Investment Management LLC’s holdings in Henry Schein were worth $664,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. MAI Capital Management boosted its holdings in Henry Schein by 7.5% in the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after buying an additional 144 shares during the period. Truist Financial Corp boosted its holdings in Henry Schein by 3.3% in the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after buying an additional 175 shares during the period. HB Wealth Management LLC boosted its holdings in Henry Schein by 1.3% in the 4th quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock worth $1,136,000 after buying an additional 191 shares during the period. Czech National Bank boosted its holdings in Henry Schein by 0.8% in the 4th quarter. Czech National Bank now owns 26,386 shares of the company’s stock worth $1,994,000 after buying an additional 206 shares during the period. Finally, Jain Global LLC boosted its holdings in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock worth $708,000 after buying an additional 207 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

HSIC opened at $74.21 on Tuesday. The firm has a 50-day simple moving average of $74.33 and a two-hundred day simple moving average of $75.71. Henry Schein, Inc. has a 52 week low of $61.94 and a 52 week high of $89.29. The company has a market capitalization of $8.45 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 1.86 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the prior year, the firm earned $1.15 EPS. The business’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts forecast that Henry Schein, Inc. will post 5.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on HSIC shares. Mizuho dropped their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. BTIG Research began coverage on shares of Henry Schein in a report on Thursday, April 16th. They set a “neutral” rating for the company. UBS Group reissued a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. Finally, Citigroup began coverage on shares of Henry Schein in a report on Wednesday, April 15th. They set a “buy” rating and a $100.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $86.83.

Insider Activity

In other news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director directly owned 15,420 shares in the company, valued at approximately $1,217,563.20. This represents a 15.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mark E. Mlotek sold 5,925 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total transaction of $478,740.00. Following the sale, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 105,911 shares of company stock worth $8,574,982. 0.89% of the stock is owned by insiders.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.